Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Uninterrupted ibrutinib with CAR T may boost outcomes in CLL

Gauthier J et al. ASH 2018, Abstract 299

Publish date:: February 14, 2019

Key clinical point: Continuing ibrutinib during CAR T-cell therapy in patients with chronic lymphocytic leukemia appears to improve outcomes and reduce risk of severe cytokine release syndrome.

Major finding: Severe cytokine release syndrome occurred in 0% versus 25% of patients in the ibrutinib and no-ibrutinib cohorts, respectively.

Study details: A retrospective comparison of 43 patients in two cohorts from a phase 1/2 study.

Disclosures: Dr. Gauthier reported having no financial disclosures.

Read the Article.

Citation:

Gauthier J et al. ASH 2018, Abstract 299

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,